TY - JOUR
T1 - Generation and characterization of novel co-stimulatory anti-mouse TNFR2 antibodies
AU - Segués, Aina
AU - van Duijnhoven, Sander M J
AU - Parade, Marc
AU - Driessen, Lilian
AU - Vukovic, Nataša
AU - Zaiss, Dietmar
AU - Sijts, Alice J A M
AU - Berraondo, Pedro
AU - van Elsas, Andrea
N1 - Funding Information:
This work was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement [grant numbers 765394 , 2018]. We thank T. Guyomard (Aduro Biotech Europe), J. Russo and D. Cuculescu (Cima Universidad de Navarra) for their expert technical assistance.
Funding Information:
This work was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sk?odowska-Curie grant agreement [grant numbers 765394, 2018]. We thank T. Guyomard (Aduro Biotech Europe), J. Russo and D. Cuculescu (Cima Universidad de Navarra) for their expert technical assistance.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/12
Y1 - 2021/12
N2 - Tumor necrosis factor receptor 2 (TNFR2) has gained much research interest in recent years because of its potential pivotal role in autoimmune disease and cancer. However, its function in regulating different immune cells is not well understood. There is a need for well-characterized reagents to selectively modulate TNFR2 function, thereby enabling definition of TNFR2-dependent biology in human and mouse surrogate models. Here, we describe the generation, production, purification, and characterization of a panel of novel antibodies targeting mouse TNFR2. The antibodies display functional differences in binding affinity and potency to block TNFα. Furthermore, epitope binding showed that the anti-mTNFR2 antibodies target different domains on the TNFR2 protein, associated with varying capacity to enhance CD8+ T-cell activation and costimulation. Moreover, the anti-TNFR2 antibodies demonstrate binding to isolated splenic mouse Tregs ex vivo and activated CD8+ cells, reinforcing their potential use to establish TNFR2-dependent immune modulation in translational models of autoimmunity and cancer.
AB - Tumor necrosis factor receptor 2 (TNFR2) has gained much research interest in recent years because of its potential pivotal role in autoimmune disease and cancer. However, its function in regulating different immune cells is not well understood. There is a need for well-characterized reagents to selectively modulate TNFR2 function, thereby enabling definition of TNFR2-dependent biology in human and mouse surrogate models. Here, we describe the generation, production, purification, and characterization of a panel of novel antibodies targeting mouse TNFR2. The antibodies display functional differences in binding affinity and potency to block TNFα. Furthermore, epitope binding showed that the anti-mTNFR2 antibodies target different domains on the TNFR2 protein, associated with varying capacity to enhance CD8+ T-cell activation and costimulation. Moreover, the anti-TNFR2 antibodies demonstrate binding to isolated splenic mouse Tregs ex vivo and activated CD8+ cells, reinforcing their potential use to establish TNFR2-dependent immune modulation in translational models of autoimmunity and cancer.
KW - Antibody
KW - Costimulation
KW - Cysteine-rich domain
KW - Epitope
KW - TNFR2
KW - Treg
UR - http://www.scopus.com/inward/record.url?scp=85117881924&partnerID=8YFLogxK
U2 - 10.1016/j.jim.2021.113173
DO - 10.1016/j.jim.2021.113173
M3 - Article
C2 - 34699840
SN - 0022-1759
VL - 499
SP - 1
EP - 9
JO - Journal of Immunological Methods
JF - Journal of Immunological Methods
M1 - 113173
ER -